The dasatinib (D)+quercetin (Q) senolytic combination exploits differential dependencies on the Bcl-2 family anti-apoptotic network between senescent and non-senescent cells, with senescent neurons exhibiting elevated p16Ink4a expression and increased sensitivity to Bcl-2/Bcl-xL inhibition. D is a tyrosine kinase inhibitor that disrupts the AKT/FOXO3a survival pathway in senescent neurons, while Q is a natural flavonoid that inhibits PI3K/AKT signaling and suppresses HSP90-mediated stabilization
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.72
Evidence
0.75
Novelty
0.68
Feasibility
0.80
Impact
0.73
Druggability
0.00
Safety
0.00
Competition
0.00
Data
0.00
Reproducible
0.55
KG Connect
0.50
Score Breakdown
Dimension
Dasatinib plus Quercetin Senol
Mechanistic
0.720
Evidence
0.750
Novelty
0.680
Feasibility
0.800
Impact
0.730
Druggability
0.000
Safety
0.000
Competition
0.000
Data
0.000
Reproducible
0.550
KG Connect
0.500
Evidence
Dasatinib plus Quercetin Senolytic Clearance of p16Ink4a-Hig